



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	329589	METAGENICS ULTRA FLORA RESTORE
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	Metagenics (Aust) Pty Ltd	
<b>Postal Address</b>	PO Box 675, VIRGINIA BC, QLD, 4014 Australia	
<b>ARTG Start Date</b>	7/02/2020	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . METAGENICS ULTRA FLORA RESTORE

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	7/02/2020
---------------------	-------------------------	-----------------------	-----------

### Permitted Indications

Traditionally used in Eclectic medicine to trophorestorative/restore organ health

Maintain/support general health and wellbeing

Maintain/support body tissue repair/regeneration

Maintain/support healthy digestive system function

Maintain/support healthy digestion

Maintain/support digestive system health

Maintain/support intestinal good/beneficial/friendly flora

Helps enhance/improve/promote/increase healthy digestive system flora/good bacteria growth

Maintain/support gastrointestinal system health

Maintain/support immune system health in children

Maintain/support immune system health

Maintain/support healthy immune system function in children

Maintain/support healthy immune system function

Maintain/support healthy gastrointestinal immune function

Maintain/support healthy gastrointestinal immune function in children

### Indication Requirements

Product presentation must not imply or refer to serious immunological diseases.

Product presentation must not imply or refer to disease in any body organ.



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

**Standard Indications**

No Standard Indications included on Record

**Specific Indications**

No Specific Indications included on Record

**Warnings**

Products containing bovine colostrum powder contain lactose and cow's milk proteins (or words to that effect). This product is not suitable for use in children under the age of 12 months except on professional health advice.

If symptoms persist consult your healthcare practitioner (or words to that effect).

**Additional Product information**

**Pack Size/Poison information**

**Pack Size**

**Poison Schedule**

**Components**

**1 . Formulation 1**

**Dosage Form** Capsule, hard

**Route of Administration** Oral

**Visual Identification**

**Active Ingredients**

<b>Bifidobacterium lactis</b>	<b>11.5 billion organisms</b>
<b>bovine colostrum powder</b>	<b>62 mg</b>
<b>Lactobacillus acidophilus</b>	<b>11.5 billion organisms</b>
<b>Lactobacillus rhamnosus</b>	<b>2 billion organisms</b>

**Other Ingredients (Excipients)**

**disodium edetate**

**gellan gum**

**hypromellose**

**magnesium stearate**

**maltodextrin**

**potable water**

**potassium acetate**

**silicon dioxide**

**sodium ascorbate**

**sucrose**

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary